secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001193125-24-061344
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista appoints Benjamin Palleiko as CEO; Crockett resigns in planned transition
--------------------------------------------------------------------------------

- T. Andrew Crockett resigned as CEO and board director effective March 6, 2024, not due to any disagreement.
- Benjamin L. Palleiko appointed CEO and to the Board; he was President/CBO/CFO and remains principal financial officer.
- Palleiko receives base salary of $661,800/year, 60% bonus target, and 250,000 RSUs vesting quarterly over 4 years.
- Crockett separation includes 18 months base salary lump sum, full FY2024 target bonus, and 150,000 RSU/PSU acceleration.
- Sebetralstat NDA filing on track for H1 2024 in US; Europe and Japan filings in H2 2024 after positive Phase 3 trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000119312524061344/0001193125-24-061344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000119312524061344/d808049d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-061344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer